Non-Small-Cell Lung Cancer – Access & Reimbursement – Detailed, Expanded Analysis (EU)


Non-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, which results in a significant financial burden on payers. Costs are set to increase following the approval of additional therapies, such as Pfizer’s Vizimpro for first-line EGFR-mutation-positive NSCLC and Astra Zeneca’s Imfinzi for unresectable Stage III NSCLC. Label expansions of existing treatments to earlier settings will also fuel costs, such as Merck & Co.’s Keytruda in first-line metastatic squamous NSCLC and unresectable Stage III NSCLC. As therapies seek to optimize their place in clinical practice, and EU5 markets strive to constrain healthcare expenditures, payers and prescribers must balance tightening budgets and evolving cost-containment policies with clinical need.


  • What are current prescribing practices for NSCLC in the EU5, and how do prescribing patterns vary by country?
  • How do surveyed prescribers and payers across the EU5 embrace newly launched therapies, such as Vizimpro and Alunbrig? How will prescribing patterns change with the launch of novel agents for NSCLC?
  • What key market access challenges will manufacturers of novel NSCLC therapies face? What can they do to encourage optimal pricing and reimbursement terms, and to drive uptake?
  • How might evolving healthcare reforms and cost-containment strategies affect reimbursement of novel agents, and to what degree will prescribing constraints present a future hurdle for emerging therapies in the EU5?


European Access & Reimbursement provides integrated brand-level and country-specific analysis of primary market research conducted with payers and prescribers to examine reimbursement dynamics and evaluate the impact of payer policy on prescribing behavior.


France, Germany, Italy, Spain, and United Kingdom


  • Survey of 250 medical oncologists across the top 5 European markets (50 per country)
  • Interviews with 10 payers top 5 European markets (2 per country).


Keytruda, Opdivo, Tecentriq, Imfinzi, Tagrisso, Tafinlar, Mekinist, Vizimpro, Tarceva, Zykadia, Xalkori, Alunbrig, Alecensa, Avastin, Abraxane, Alimta, Giotrif, Cyramza


  • Actionable recommendations to optimize market access
  • Market access success and stumbles
  • Market access roadblocks
  • Pricing and reimbursement dynamics
  • Impact of payer policy and coverage on prescribing
  • Market access outlook for emerging therapies

launch Related Market Assessment Reports